T7572
トロンビン ヒト血漿由来
400-1000 NIH units/mg protein
別名:
第 IIa因子
ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
CAS番号:
UNSPSC Code:
12352204
NACRES:
NA.54
EC Number:
232-648-7
MDL number:
Analysis Note
NIHのアッセイでは、Biggs法の変法に基づいて、トロンビンサンプル(1%緩衝アルブミン溶液で安定化)0.1 mLと、基質として希釈血漿(同量の生理食塩水で希釈)0.2 mLを用います。凝固時間が15～25秒の範囲のものだけを用いてトロンビン濃度を決定します。
Biochem/physiol Actions
Arg-Glyを選択的に切断するセリンプロテア-ゼは、フィブリノ-ゲン内に結合し、フィブリンおよびfibrinopeptide A、Bを形成します。
General description
凍結乾燥品(スクロ-ス, 塩化ナトリウム, Trisバッファ-塩を含有)
Thrombin is the final coagulation protease in regard to hemostasis, promoting both procoagulant and anticoagulant effects.
Other Notes
より詳細な情報につきましては、www.sigma-aldrich.com/enzymeexplorerの「 thrombin」をご覧ください。
活性は、NIHトロンビンスタンダ-ドとの直接比較によって得られるNIH unitで表しています。
Application
Thrombin is used for site specific cleavage of recombinant fusion proteins containing an accessible thrombin recognition site for removal of affinity tags. Thrombin has been used in a study to assess an innovative flow cytometric approach for small-size platelet microparticles.
Disclaimer
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
An innovative flow cytometric approach for small-size platelet microparticles: influence of calcium.
Silvia Montoro-García et al.
Thrombosis and haemostasis, 108(2), 373-383 (2012-06-29)
Microparticles (MPs) are small submicron membrane-derived vesicles shed from a variety of cells and they have been implicated in different disorders. Accordingly, understanding of physiological characteristics of MPs and improvement of methods of their quantification are important for further advance
At the cutting edge: conformational PARtiality.
T Madhusudhan et al.
Journal of thrombosis and haemostasis : JTH, 10(8), 1672-1674 (2012-06-30)
Jawed Fareed et al.
Annual review of pharmacology and toxicology, 52, 79-99 (2011-08-09)
Since the discovery of heparin nearly a century ago, there have been large gaps in the development of anticoagulants. The discovery of warfarin was the first step toward using oral anticoagulants, but warfarin use has been associated with its own
Herbert Nar
Trends in pharmacological sciences, 33(5), 279-288 (2012-04-17)
The quest for novel medications to treat thromboembolic disorders such as venous thrombosis, pulmonary embolism and stroke received a boost when the 3D structures of two major players in the blood coagulation cascade were determined in 1989 and 1993. Structure-guided
Christopher S King et al.
Chest, 143(4), 1106-1116 (2013-04-03)
Thromboembolic diseases are common. Heparins and the vitamin K antagonists have been the mainstay of therapy for > 60 years, but both classes of agents have limitations. The "ideal" anticoagulant should be as effective and safe as heparin and vitamin
資料
Thrombin Factor IIa is an endolytic serine protease that selectively cleaves the Arg--Gly bonds of fibrinogen to form fibrin and release fibrinopeptides A and B.
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）